The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development

组蛋白赖氨酸甲基转移酶KMT2D维持着一个抑制B细胞淋巴瘤发展的基因表达程序。

阅读:8
作者:Ana Ortega-Molina ,Isaac W Boss ,Andres Canela ,Heng Pan ,Yanwen Jiang ,Chunying Zhao ,Man Jiang ,Deqing Hu ,Xabier Agirre ,Itamar Niesvizky ,Ji-Eun Lee ,Hua-Tang Chen ,Daisuke Ennishi ,David W Scott ,Anja Mottok ,Christoffer Hother ,Shichong Liu ,Xing-Jun Cao ,Wayne Tam ,Rita Shaknovich ,Benjamin A Garcia ,Randy D Gascoyne ,Kai Ge ,Ali Shilatifard ,Olivier Elemento ,Andre Nussenzweig ,Ari M Melnick ,Hans-Guido Wendel

Abstract

The gene encoding the lysine-specific histone methyltransferase KMT2D has emerged as one of the most frequently mutated genes in follicular lymphoma and diffuse large B cell lymphoma; however, the biological consequences of KMT2D mutations on lymphoma development are not known. Here we show that KMT2D functions as a bona fide tumor suppressor and that its genetic ablation in B cells promotes lymphoma development in mice. KMT2D deficiency also delays germinal center involution and impedes B cell differentiation and class switch recombination. Integrative genomic analyses indicate that KMT2D affects methylation of lysine 4 on histone H3 (H3K4) and expression of a set of genes, including those in the CD40, JAK-STAT, Toll-like receptor and B cell receptor signaling pathways. Notably, other KMT2D target genes include frequently mutated tumor suppressor genes such as TNFAIP3, SOCS3 and TNFRSF14. Therefore, KMT2D mutations may promote malignant outgrowth by perturbing the expression of tumor suppressor genes that control B cell-activating pathways.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。